{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-023724","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.612202+00:00","generated_at":"2026-05-17T13:47:39.991834+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Enveric Biosciences Q2 net loss $2.5M; EB-003 dual mechanism disclosed, IND on track for early 2026","bullets":["Net loss $2.5M ($0.97/shr) vs $1.9M ($3.72/shr) in Q2 2024; cash $2.8M at June 30.","Raised $4.9M net proceeds in first half 2025 via financing tools.","EB-003 reveals dual agonism at 5-HT2A (partial) and 5-HT1B receptors, a novel class.","IND submission for EB-003 expected early 2026; preclinical models show PTSD and depression efficacy.","Expanded IP portfolio: new patent filed, allowance for mescaline-derivative and tryptamine patents."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-023724","json":"https://secwatch.observer/filing/0001641172-25-023724.json","markdown":"https://secwatch.observer/filing/0001641172-25-023724.md","text":"https://secwatch.observer/filing/0001641172-25-023724.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000164117225023724/0001641172-25-023724-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000164117225023724/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:47:39.991834+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}